Joshua J. Meeks
Advanced in WT1-Related Wilms Tumor Syndromes

Dr. Joshua J. Meeks

Oncology
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
Offers Telehealth
20 Years of Experience
Advanced in WT1-Related Wilms Tumor Syndromes
675 N St Clair St Ste 20-150, Galter Pavilion, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Joshua Meeks is an Oncologist in Chicago, Illinois. Dr. Meeks has been practicing medicine for over 20 years and is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Orchiectomy, and Reconstructive Urology Surgery.

His clinical research consists of co-authoring 163 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Northwestern University Feinberg School Of Medicine, 2005
Specialties
Oncology
Licenses
Urology in IL
Board Certifications
American Board Of Urology - Urology (Certified)
Hospital Affiliations
Northwestern Memorial Hospital
Northwestern Lake Forest Hospital
Northwestern Medicine Mchenry
Palos Community Hospital
Northwestern Medicine Central Dupage Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

675 N St Clair St Ste 20-150, Galter Pavilion, Chicago, IL 60611

Additional Areas of Focus

Dr. Meeks has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Bladder Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2025
Intervention Type: Other, Dietary supplement
Study Phase: Phase 3
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Enrollment Status: Completed
Publish Date: September 25, 2024
Intervention Type: Biological, Other
Study Drugs: Engineered Oncolytic Adenovirus, Pembrolizumab, N-Dodecyl-B-D-Maltoside
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Pembrolizumab
Study Phase: Phase 1
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma
Enrollment Status: Terminated
Publish Date: May 01, 2019
Intervention Type: Other, Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

163 Total Publications

PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive Bladder Cancer: Erratum.
Journal: The Journal of urology
Published: October 09, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey Sosman
Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeffrey Sosman
Hematology | Oncology
675 N Saint Clair St Ste 21-100, 
Chicago, IL 
 (0.1 miles away)
312-695-0990
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Sosman is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Sosman is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Melanoma, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and Nephrectomy.

Timothy M. Kuzel
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy M. Kuzel
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Timothy M. Kuzel
Oncology
15300 West Ave Ste 100A, 
Orland Hills, Illinois, IL 
 (21.8 miles away)
630-232-0280
Experience:
41+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Timothy Kuzel is an Oncologist in Orland Hills, Illinois, Illinois. Dr. Kuzel has been practicing medicine for over 41 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Cutaneous T-Cell Lymphoma (CTCL), Prostate Cancer, and Prostatectomy.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Walter M. Stadler
Hematology Oncology | Hematology | Oncology

City Of Hope Medical Group Of Illinois PLLC

2520 Elisha Ave, 
Zion, IL 
 (39.7 miles away)
847-872-4561
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients

Walter Stadler is a Hematologist Oncology specialist and a Hematologist in Zion, Illinois. Dr. Stadler is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Orchiectomy, and Nephrectomy. Dr. Stadler is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Meeks's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 8 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile